The application generally relates to olfaction as a biomarker, more particularly as a prognostic biomarker or biological predictor, of neurosensory disease or disorder and/or of neurocognitive disease or disorder, in subjects whose nervous system has been infected by an infectious agent, such as by a neurotropic virus, bacterium, protozoan parasite, fungus or prion, more particularly by a neurotropic virus.

Described here is a deep brain stimulation (“DBS”) approach that targets several relevant nodes within brain circuitry, while monitoring multiple symptoms for efficacy. This approach to multi-symptom monitoring and stimulation therapy may be used as an extra stimulation setting in extant DBS devices, particularly those equipped for both stimulation and sensing. The therapeutic efficacy of DBS devices is extended by optimizing them for multiple symptoms (such as sleep disturbance in addition to movement disorders), thus increasing quality of life for patients.

A system for identifying abnormal eye movements includes a near-eye display (NED), an eye-tracking camera, a frame supporting the NED and the eye-tracking camera, and a processor in data communication with the NED, the eye-tracking camera, and a computer readable medium. The computer readable medium has instructions thereon. When executed by the processor, the instructions cause the processor to provide a target on the NED to a user's eye and change the target or move the target to a plurality of locations in three dimensions on the NED according to one or more tasks of a task module. The processor further records positional information and pupil information of the user's eye during the one or more tasks of the task module and compares the positional information to at least one threshold value of an abnormality identification algorithm.

Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins.

An example method includes, determining, based on data received from a plurality of sensors that are each attached to a respective finger of a plurality of fingers of a hand of a patient, data that represents movements of one or more fingers of the plurality of fingers; and determining, based on the data that represents the movements of the one or more fingers, one or more objective indications of motor control of the patient.

Described are methods, devices, and systems for a novel, inexpensive, easy to use therapy for treatment of anxiety. Described are methods and devices to treat anxiety that involves no medication. Methods and devices described herein use alternating magnetic fields to gently “tune” the brain and affect symptoms of anxiety.

The present invention is directed to a device and method for monitoring and assessment of movement disorder symptoms. The device and method disclosed herein are particularly amenable to remote monitoring of a subject's movement disorder symptoms. Briefly stated, in certain preferred embodiments of the present invention the movement disorder monitoring device accompanies a subject to a remote location where the device is used to record data relating to the severity of a subject's movement disorder symptoms over a period of time. This data is then subsequently used by physicians or other clinicians in optimizing and assessing treatment options directed at alleviating a subject's movement disorder symptoms. The method and device of the present invention can be used to monitor symptoms of a number of movement disorders including but not limited to dystonia, essential tremor, Huntington's disease, various ataxias, multiple sclerosis, psychogenic tremor, and Parkinson's disease.

The present invention provides methods for identifying biomarkers of disease capable of affecting cognitive function. The biomarkers identified by the methods of the prevention may be used for predicting whether a mammal will develop a disease capable of affecting cognitive function. More specifically, the present invention relates to the identification of biomarkers predictive of neurological diseases in a mammal and the use of these biomarkers in the diagnosis, differential diagnosis, and/or prognosis of the neurological disease. The methods and systems provided enable an assessment and theoretical prediction of neocortical amyloid loading based on the measurement of biomarkers that will provide an indication of whether a mammal is likely to develop a neurological disease.

The present disclosure provides an operating method of a dopamine transporter check system, and the operation method includes steps as follows. A scan image of a subject's brain is obtained from a scan machine, and the scan image is a three-dimensional image. The scan image is aligned to a standard brain space to obtain a standardized scan image. Intensity normalization is performed on the standardized scan image. The standardized scan image after the intensity normalization is converted into a two-dimensional image. A plurality of image data are got from at least one region of interest in the two-dimensional image, and the at least one region of interest includes a left caudate, a left putamen, a right caudate and a right putamen. A dopamine neuron loss degree measurement and evaluation model based on the image data is established through a transfer learning.

Provided are systems, methods, and kits for multifunctional smell assessment. The kits may comprise a first surface adhered by a first releasable adhesive comprising an odorous volatile compound; and the system for registering if the odorous volatile compound is detected by a user. The system or method may comprise queries for obtaining a first input on whether the user detects and identifies the odorous volatile compound, and an intensity by which the odor is perceived.